Myriad Genetics Inc. MYGN reported adjusted earnings per share (EPS ... It has a four-quarter average earnings surprise of 8.45%. Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the …
Yahoo!9mon
Myriad Genetics, Inc. MYGN presented encouraging data from a study to evaluate ... Over the past year, the company’s share price has outperformed the broader industry. The stock has gained 90.1%, in contrast to the broader industry’s …
Investors found another reason to bid up shares of Myriad Genetics Inc. /quotes/zigman/58124 /quotes/nls/mygn MYGN, which is sole owner of ... hitting a fresh 52-week high. The stock surged last week on third-quarter results that …
Myriad Genetics would be listed on the New York Stock Exchange under the ticker symbol “MGX”, and Myriad Pharmaceuticals will be listed on Nasdaq under the company’s current ticker symbol “MYGN.” Myriad has retained J.P. …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has surged roughly 77.9% over a year. …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 83.9% over a year. …
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $37.30 to a high of $39.64. Yesterday, the shares fell 8.0%, which took the trading range below the 3-day low of $40.21 on volume of 993,000 …
2. Myriad Genetics Inc. (MYGN) Gained 20.45% to close Wednesday's trading at $22.50. News: The Company reported better-than-expected fiscal third-quarter 2017 results and provided rosy outlook for fiscal fourth quarter and full year. For …
Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the …